Cargando…

Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer

Historically, understanding of acquired resistance (AQR) to combination treatment has been based on knowledge of resistance to its component agents. To test whether an altered drug interaction could be an additional factor in AQR to combination treatment, models of AQR to combination and single agen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattacharya, Bhaskar, Low, Sarah Hong Hui, Chong, Mei Ling, Chia, Dilys, Koh, King Xin, Sapari, Nur Sabrina, Kaye, Stanley, Hung, Huynh, Benoukraf, Touati, Soong, Richie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045388/ https://www.ncbi.nlm.nih.gov/pubmed/27081080 http://dx.doi.org/10.18632/oncotarget.8692

Ejemplares similares

Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
por: Koh, King Xin, et al.
Publicado: (2017)

Clinical Potential of DNA Methylation in Gastric Cancer: A Meta-Analysis
por: Sapari, Nur Sabrina, et al.
Publicado: (2012)

GBSA: a comprehensive software for analysing whole genome bisulfite sequencing data
por: Benoukraf, Touati, et al.
Publicado: (2013)

Combined MEK and Pi3′-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo
por: ElMokh, Oussama, et al.
Publicado: (2017)

miREM: an expectation-maximization approach for prioritizing miRNAs associated with gene-set
por: Abdul Hadi, Luqman Hakim, et al.
Publicado: (2018)

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
por: Heavey, Susan, et al.
Publicado: (2016)

The Warburg effect and drug resistance
por: Bhattacharya, Bhaskar, et al.
Publicado: (2016)

eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors
por: Hijazi, Maruan, et al.
Publicado: (2022)

High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients
por: Tan, Sing-Huang, et al.
Publicado: (2015)

Correspondence on NanoVar’s performance outlined by Jiang T. et al. in “Long-read sequencing settings for efficient structural variation detection based on comprehensive evaluation”
por: Tham, Cheng Yong, et al.
Publicado: (2023)

DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach
por: Loh, Marie, et al.
Publicado: (2014)

TFregulomeR reveals transcription factors’ context-specific features and functions
por: Lin, Quy Xiao Xuan, et al.
Publicado: (2020)

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
por: Sato, Hiroki, et al.
Publicado: (2018)

E2F and STAT3 provide transcriptional synergy for histone variant H2AZ activation to sustain glioblastoma chromatin accessibility and tumorigenicity
por: Yoon, Jeehyun, et al.
Publicado: (2022)

Whole genome DNA methylation: beyond genes silencing
por: Tirado-Magallanes, Roberto, et al.
Publicado: (2016)

Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer
por: Naderi, Ali, et al.
Publicado: (2011)

Assessing the efficiency and significance of Methylated DNA Immunoprecipitation (MeDIP) assays in using in vitro methylated genomic DNA
por: Jia, Jinsong, et al.
Publicado: (2010)

Initiation of V(D)J Recombination by Dβ-Associated Recombination Signal Sequences: A Critical Control Point in TCRβ Gene Assembly
por: Franchini, Don-Marc, et al.
Publicado: (2009)

Long-Range Regulatory Synergy Is Required to Allow Control of the TAC1 Locus by MEK/ERK Signalling in Sensory Neurones
por: Shanley, Lynne, et al.
Publicado: (2011)

MethMotif: an integrative cell specific database of transcription factor binding motifs coupled with DNA methylation profiles
por: Xuan Lin, Quy Xiao, et al.
Publicado: (2019)

Increased intron retention is a post‐transcriptional signature associated with progressive aging and Alzheimer’s disease
por: Adusumalli, Swarnaseetha, et al.
Publicado: (2019)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
por: Jokinen, Elina, et al.
Publicado: (2012)

Synergy Repetition Training versus Task Repetition Training in Acquiring New Skill
por: Patel, Vrajeshri, et al.
Publicado: (2017)

Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells
por: Tsubaki, Masanobu, et al.
Publicado: (2019)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer
por: Blas, Kevin, et al.
Publicado: (2018)

A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
por: Yang, Shujie, et al.
Publicado: (2011)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
por: Izquierdo, Elisa, et al.
Publicado: (2022)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
por: Lee, Lawrence Soon-U, et al.
Publicado: (2016)

Mek1 and Mek2 Functional Redundancy in Erythropoiesis
por: Beuret, Laurent, et al.
Publicado: (2021)

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
por: Hata, Aaron N, et al.
Publicado: (2017)

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells
por: Jin, W, et al.
Publicado: (2003)

Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis
por: Madala, Satish K., et al.
Publicado: (2014)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy
por: Chang, Raymond, et al.
Publicado: (2019)

Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
por: Du, Wei, et al.
Publicado: (2021)

Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells
por: Bhattacharya, Bhaskar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rni1hssdvqtnqd80hideci2634